Quality of Life in Asthma and Rhinitis Allergic With Singulair (0476-365)

• Status: Completed
• Trial end date: 2005-07-29
• Target enrollment: 0
• Participant gender: All

Summary

Allow physicians not familiar with anti-leukotriene based therapy to test it

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Montelukast

Criteria

Inclusion Criteria:

• Establish diagnosis of mild to moderate chronic asthma and/or allergic rhinitis currently on treatment

• Voluntary acceptance to participate in the study

Exclusion Criteria:

• Patients with cystic fibrosis

• Patients with known hypersensitivity to singulair or any of its components

• Patients with severe chronic asthma